DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,241 filers reported holding DANAHER CORPORATION in Q2 2018. The put-call ratio across all filers is 0.63 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $914,745 | +3.4% | 3,687 | 0.0% | 0.41% | +4.5% |
| Q2 2023 | $884,880 | -4.8% | 3,687 | 0.0% | 0.40% | -3.4% |
| Q1 2023 | $929,271 | -5.0% | 3,687 | 0.0% | 0.41% | -17.3% |
| Q4 2022 | $978,604 | +0.7% | 3,687 | -2.0% | 0.50% | -10.5% |
| Q3 2022 | $972,000 | +1.9% | 3,762 | 0.0% | 0.55% | +22.6% |
| Q2 2022 | $954,000 | -13.6% | 3,762 | 0.0% | 0.45% | +71.9% |
| Q1 2022 | $1,104,000 | -10.8% | 3,762 | 0.0% | 0.26% | -4.0% |
| Q4 2021 | $1,238,000 | +6.7% | 3,762 | -1.3% | 0.27% | +0.7% |
| Q3 2021 | $1,160,000 | +13.5% | 3,810 | 0.0% | 0.27% | +14.3% |
| Q2 2021 | $1,022,000 | +19.1% | 3,810 | 0.0% | 0.24% | +3.9% |
| Q1 2021 | $858,000 | +1.4% | 3,810 | 0.0% | 0.23% | -10.5% |
| Q4 2020 | $846,000 | +0.5% | 3,810 | -2.6% | 0.26% | -12.0% |
| Q3 2020 | $842,000 | +21.9% | 3,910 | 0.0% | 0.29% | +46.2% |
| Q2 2020 | $691,000 | +27.7% | 3,910 | 0.0% | 0.20% | -5.7% |
| Q1 2020 | $541,000 | -19.1% | 3,910 | -10.3% | 0.21% | +12.8% |
| Q4 2019 | $669,000 | -88.0% | 4,360 | -88.7% | 0.19% | -88.0% |
| Q3 2019 | $5,559,000 | -7.1% | 38,487 | -8.0% | 1.56% | -2.7% |
| Q2 2019 | $5,981,000 | -18.7% | 41,847 | -24.9% | 1.60% | -12.3% |
| Q1 2019 | $7,358,000 | +30.3% | 55,731 | +1.8% | 1.82% | +5.4% |
| Q4 2018 | $5,645,000 | -4.2% | 54,746 | +1.0% | 1.73% | +13.1% |
| Q3 2018 | $5,891,000 | +13.3% | 54,216 | +2.9% | 1.53% | +6.3% |
| Q2 2018 | $5,198,000 | -1.8% | 52,678 | -2.5% | 1.44% | -4.4% |
| Q1 2018 | $5,291,000 | -10.7% | 54,038 | -15.4% | 1.51% | -6.6% |
| Q4 2017 | $5,926,000 | -1.8% | 63,841 | -9.3% | 1.61% | +2.0% |
| Q3 2017 | $6,035,000 | +6.0% | 70,355 | +4.3% | 1.58% | +1.5% |
| Q2 2017 | $5,695,000 | -2.5% | 67,479 | -1.2% | 1.56% | -3.1% |
| Q1 2017 | $5,841,000 | -53.9% | 68,297 | -58.0% | 1.61% | -57.7% |
| Q4 2016 | $12,659,000 | +5899.5% | 162,624 | +7070.4% | 3.80% | +3176.7% |
| Q4 2015 | $211,000 | +3.9% | 2,268 | -4.2% | 0.12% | +7.4% |
| Q2 2015 | $203,000 | +1.0% | 2,368 | 0.0% | 0.11% | +0.9% |
| Q1 2015 | $201,000 | -1.0% | 2,368 | 0.0% | 0.11% | -3.6% |
| Q4 2014 | $203,000 | -1.9% | 2,368 | -11.8% | 0.11% | -8.3% |
| Q4 2013 | $207,000 | +21.1% | 2,686 | -0.4% | 0.12% | +30.1% |
| Q2 2013 | $171,000 | +13.2% | 2,697 | +11.4% | 0.09% | -3.1% |
| Q1 2013 | $151,000 | +11.9% | 2,422 | 0.0% | 0.10% | -2.0% |
| Q4 2012 | $135,000 | – | 2,422 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |